The authors here identify ST2+ Treg cells facilitate AML growth by inducing CD8+ T cell depletion and exhaustion, while targeting ST2 by antibodies depletes ST2+ Treg cells and improves AML prognosis. The gene discussed is CD8A; the disease is acute myeloid leukemia.